TP53 and prostate carcinoma: Work from our group and others has shown that assessing p53 mutations on IHC from tissue microarrays (TMA) has not delivered the same results.11 While TMA analysis is convenient and with appropriate sampling technique is suitable for most prostate cancer biomarkers,21 our study has shown that p53 is an unusual biomarker that requires analysis of whole tissue sections and may be dismissed by the TMA method.